ArticleInternational journal of chronic obstructive pulmonary disease2017
Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.
Article in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Bidirectional association between COPD and AF: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network.BMC pulmonary medicine · 2026Observational
- A deep dive into atrial fibrillation in chronic obstructive pulmonary disease.NPJ primary care respiratory medicine · 2026Review
- Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated.Heart failure reviews · 2025Review
- Incidence, risk factors, and outcomes of respiratory related hospitalizations in older patients with COPD, asthma, and bronchiectasis.Scientific reports · 2025Article
- Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus: Complex Interactions and Clinical Implications.Journal of clinical medicine · 2025Review
- [Efficient patient preparation in computed tomography coronary angiography].Radiologie (Heidelberg, Germany) · 2024Review
- Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis.Tuberculosis and respiratory diseases · 2024Article
- Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register.Frontiers in cardiovascular medicine · 2022Article
- A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.Headache · 2021Review
- Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension.Cardiology journal · 2020Review
- Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study.Pragmatic and observational research · 2020Article
- Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.Scientific reports · 2019Article
- Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study.Heart and vessels · 2019Observational
- Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2019Article
- Different Non-selective β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease.EClinicalMedicine · 2019Article
- Beta-Blockers: A Tale of Triumphs, Trials, and Tribulations.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is conflicting information regarding the effects of selective and nonselective beta-blocker treatment in patients with COPD. PARTICIPANTS AND
methodsThis nested case-control study used the Taiwan National Health Insurance Research Database. We included COPD patients who used inhalation steroid and beta-blockers between 1998 and 2010. From this cohort, there were 16,067 patients with severe exacerbations included in the analysis and 55,970 controls matched on age, sex, COPD diagnosis year, and beta-blockers treatment duration by risk set sampling.
resultsFor the selective beta-blocker users, the current users had a lower risk of severe exacerbations than the nonusers (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.85-0.96). In contrast, for the nonselective beta-blocker users, the current users had a higher risk of severe acute exacerbations than the nonusers (OR, 1.21; 95% CI, 1.14-1.27). A higher risk of severe exacerbation during increasing mean daily dose or within about the initial 300 days was found in nonselective beta-blockers, but not in selective beta-blockers. One selective beta-blocker, betaxolol, had a significantly lower risk of severe exacerbations (OR, 0.75; 95% CI, 0.60-0.95). Two nonselective beta-blockers (labetalol and propranolol) were associated with a significantly higher risk of exacerbations (OR, 1.49; 95% CI, 1.32-1.67 for labetalol; OR, 1.16; 95% CI, 1.10-1.23 for propranolol).
conclusionSelective beta-blockers can be cautiously prescribed for patients with COPD and cardiovascular disease (CVD), however, nonselective beta-blockers should not be prescribed for patients with COPD. Betaxolol may be the preferred choice of suitable selective beta-blocker for patients with COPD, however, labetalol and propranolol should be avoided for patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.